Study to Evaluate Systemic Bioavailability of Oral OTS167 in Healthy Adult Subjects

NCT02768519 | Completed Phase 1

• 1 other identifier: OTS167-FR03
• Study Type: interventional
• Target: 11
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine the indicative bioavailability of a single oral dose of OTS167, and to evaluate the effects of food on OTS167 pharmacokinetics (PK) after oral dosing. Eleven male and female healthy participants aged 45 years and over will be entered into this phase 1, single-centre, double-blind, randomised, cross-over study. The trial is designed to evaluate the bioavailability of OTS167, and the effects of food on pharmacokinetics (PK) of OTS167 when administered by the oral route. Correlative studies include evaluation of safety endpoints and examinations, and adverse events. This study involves 3 cohorts to evaluate the safety and tolerability of oral dosing from lower dose.

Conditions

Healthy

Keywords

Participants

Outcome Measures

Primary Outcomes (5)

• Safety: Participants to be monitored throughout the treatment and follow-up period for occurrence of adverse events (AEs) (acute, delayed, and/or cumulative), as well as for changes in clinical status, vital signs, and laboratory data.

  Safety assessments include concomitant medication survey, adverse events, temperature, pulse and respiratory rate, blood pressure, physical examination, hematologic parameters, serum chemistries, coagulation parameters, urinalyses, and 12-Lead ECG and cardiac telemetry.

  7 days after final study drug administration.

• Maximum Plasma Concentration (Cmax)

  24 hours after final study drug administration.

• Time of Maximum concentration (Tmax)

  24 hours after final study drug administration.

• Area Under the Curve (AUC)

  24 hours after final study drug administration.

• Half life (T1/2)

  24 hours after final study drug administration.

Study Arms (2)

OTS167IV

EXPERIMENTAL

Cohort 1: 0.5 mg, Cohort 2: 1.0 mg, and Cohort 3: 2.0 mg without food on Period 1 Day 1 and with food on Day 1 Period 2.

Drug: OTS167IV

Placebo

PLACEBO COMPARATOR

Cherry syrup

Other: Cherry syrup

Interventions

OTS167IV DRUG

diluted to final concentration with cherry syrup

OTS167IV

Cherry syrup OTHER

Placebo

Eligibility Criteria

• Age: 45 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Males or females aged 45 years or over.
• Female participants of non-childbearing potential, meeting at least one of the following criteria:
• Amenorrhoeal for 12 months (menopause confirmed by Follicular Stimulating Hormone (FSH) and Luteinising Hormone (LH) levels as defined by the established reference ranges), or
• Surgically sterile (e.g. hysterectomy, oophorectomy, tubal ligation) for at least the past 3 month.
• Able to communicate with site personnel and to understand and voluntarily sign the Informed Consent Form (ICF).
• Able and willing to comply with the protocol, including availability for all scheduled study visits.
• Body mass index (BMI) 18 kg/m2 to 30 kg/m2 (inclusive)
• No clinically significant abnormalities as determined by medical history, physical examination, blood chemistry, hematology, urinalysis, and 12-lead electrocardiogram (ECGs).
• If male, agrees to use a medically acceptable method of contraception from Screening until 7 days after administration of the last dose of study drug. Medically acceptable methods of contraception include the following: abstinence; medically approved hormonal methods; condom; diaphragm; and intrauterine device. This requirement may be waived if the Principal Investigator or delegate is satisfied that the participant or partner is sterile (i.e., if female has undergone a hysterectomy, or has undergone a tubal ligation at least 3 months prior to Screening, or is postmenopausal \[no menstrual period for at least 12 months prior to Screening\]; if male, has undergone vasectomy at least 6 months prior to Screening). Male participants agree not to donate sperm for at least 90 days \[3 months\] after administration of the last dose of study drug.
• Agree to avoid drinking alcohol within 72 hours prior to check-in to the clinical facility.
• Adequate venous access in the left and right arm to allow collection of a number of blood samples.

You may not qualify if:

• Evidence or history of clinical significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic diseases
• Orthostatic blood pressure changes (\>15mmHg) or symptoms, or presence of uncontrolled hypertension (SBP \>160 mmHg or diastolic \>95 mmHg) at screening, admission (Day -1) or pre-dose (Day 1).
• Greater than 2 standard drinks per day, on average, for men and women, or any history of drug or alcohol addiction or abuse within the last 5 years.
• History of allergic, anaphylaxis or hypersensitivity to OTS167 or excipients or contents of Humco ™ cherry syrup.
• Female participants who are currently lactating.
• Donated either blood or plasma (e.g., plasmapheresis) within 6 weeks prior to dosing in Period 1. All participants must be advised not to donate either blood or plasma for at least 6 weeks after completing the study.
• Use of prescription medications (with the exception of contraceptives), over-the-counter medications (with the exception of paracetamol \[\< 2 gm/day\] or single-dose daily multivitamins), or herbal medications or products containing herbal extracts within 14 days prior to the first dose.
• Positive results on illicit drug test or alcohol breath test at screening or at admission.
• Positive screening test for HIV antibodies, Hepatitis B surface antigen or Hepatitis C antibody.
• Use of any investigational drug within the last 30 days or within a period of 5 times the drug's half-life, whichever is longer, or current participation in any investigational protocol.
• Participants who, in the opinion of the Principal Investigator or delegate, should not participate in the study or are not capable of following the study schedule for any reason.
• Either QTcF \>450 or HR \<40 or \>100 at screening, admission (Day-1) or pre-dose (Day 1). Test may be repeated at discretion of investigator to obtain average in order to confirm eligibility.

Sponsors & Collaborators

• OncoTherapy Science, Inc.: lead

Study Sites (1)

CMAX, Royal Adelaide Hospital

Adelaide, South Australia, 5000, Australia

Location

Study Officials

• Sepehr Shakib

  CMAX (A division of IDT Australia Ltd)

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 13, 2016
• First Posted: May 11, 2016
• Study Start: January 1, 2016
• Primary Completion: February 1, 2016
• Study Completion: February 1, 2016
• Last Updated: June 1, 2017

Record last verified: 2017-05

Locations

AU (1)